论文部分内容阅读
目的 :探讨血浆凝血酶激活的纤溶抑制物(thrombin-activated fibrinolysis inhibitor,TAFI)和凝血酶-抗凝血酶(thrombin-antithrombin,TAT)复合物水平与胃癌的关系。方法 :收集2012年1月—2014年5月由江门市中心医院收治的52例胃癌患者、32例胃良性疾病患者和48例健康志愿者的血液标本,应用ELISA法检测血浆中TAT和TAFI水平,采用全自动血凝分析仪检测血浆中纤维蛋白原和D-二聚体水平。结果 :胃癌患者血浆中TAFI、TAT、纤维蛋白原和D-二聚体的水平均高于胃良性疾病患者和健康志愿者(P值均<0.05),而胃良性疾病患者与健康志愿者之间的差异无统计学意义(P值均>0.05)。胃癌患者血浆中TAFI和TAT的水平与淋巴结转移有关(P值均<0.05)。结论 :胃癌患者血浆中TAFI和TAT的水平升高,与胃癌有一定的相关性。
Objective: To investigate the relationship between plasma thrombin-activated fibrinolysis inhibitor (TAFI) and thrombin-antithrombin (TAT) complex and gastric cancer. Methods: Blood samples of 52 gastric cancer patients, 32 gastric benign disease patients and 48 healthy volunteers were collected from January 2012 to May 2014 in Jiangmen Central Hospital. TAT and TAFI levels in plasma were detected by ELISA , Using automatic hemagglutination analyzer plasma fibrinogen and D-dimer levels. Results: The levels of plasma TAFI, TAT, fibrinogen and D-dimer in patients with gastric cancer were significantly higher than those in patients with benign gastric diseases and healthy volunteers (all P <0.05), while patients with benign gastric diseases and healthy volunteers There was no significant difference between the two groups (P> 0.05). The levels of TAFI and TAT in plasma of gastric cancer patients were correlated with lymph node metastasis (all P <0.05). Conclusion: The plasma levels of TAFI and TAT in patients with gastric cancer are elevated, which have some correlation with gastric cancer.